Continue reading this on our app for a better experience

Open in App
Floating Button
Home Capital Results

Singapore Medical Group reports 36.1% lower FY20 earnings of $8.7 mil

Felicia Tan
Felicia Tan • 2 min read
Singapore Medical Group reports 36.1% lower FY20 earnings of $8.7 mil
The group has recommended a final dividend of 0.4 cents per share for the FY2020, the same as FY2019.
Font Resizer
Share to Whatsapp
Share to Facebook
Share to LinkedIn
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

Singapore Medical Group (SMG) has reported 36.1% lower earnings of $8.7 million for the FY2020 ended December, from earnings of $13.7 million in the year before.

FY2020 group revenue fell 7.7% y-o-y to $87.3 million due to lower revenue from its Diagnostic & Aesthetics Business and Health Business segments.

The lower revenue from both segments were attributable to lower patient volumes from the deferment of non-essential medical services and the temporary closure of certain clinics during the circuit breaker period from April to June 2020.

Gross profit for the FY2020 fell 12% y-o-y to $38 million due to the decrease in revenue, leading to a 2 percentage point dip in gross profit margin (GPM) to 44%.

For more stories about where the money flows, click here for our Capital section

Other loss in FY2020 is due to impairment loss recognised on goodwill from the acquisition of three paediatrics clinics in 2017, compared to other gain in FY2019.

Share of profit of joint ventures and associates grew by 65.9% y-o-y to $0.5 million due to profits from its associated company, CHA SMG (Australia).

As at Dec 31, 2020, cash and cash equivalents stood at $25.6 million.

The group has recommended a final dividend of 0.4 cents per share for the FY2020, the same as FY2019.


SEE: UOBKH ups Singapore Medical Group's TP on 'attractive' valuation

“FY2020 was a challenging year as the impact from Covid-19 weighed on our operations. While our diversified business model remained resilient, we were fortunate to have benefitted from governmental wage and rental support,” says SMG’s executive director and CEO Beng Teck Liang.

“As a result of structural and regulatory shifts across the paediatrics landscape in Singapore, we took a prudent approach to recognise a non-cash impairment loss on goodwill on our Paediatrics Business Unit as the outlook has become increasingly challenging and uncertain. Despite the headwinds, we were encouraged by the strong demand for our Aesthetics, Lasik, Dental and Health Screening services as consumer discretionary spending continued to hold during the year,” Beng adds.

Shares in SMG closed 2 cents lower or 4.8% down at 40 cents on Feb 19.

Highlights

Re test Testing QA Spotlight
1000th issue

Re test Testing QA Spotlight

×
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
© 2024 The Edge Publishing Pte Ltd. All rights reserved.